Latest information on COVID-19
Support teaching, research, and patient care.
Please see my home page for full descriptions of research: www.stanford.edu/people/yesavage
Estrogen Use in Protection From Cognitive Decline Not Recruiting
This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.
Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
View full details
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol Not Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
Citalopram for Agitation in Alzheimer's Disease Not Recruiting
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
Treatments for Insomnia: Mediators, Moderators and Quality of Life Not Recruiting
The purpose of this study is to evaluate the relative efficacy and effectiveness of specific components of cognitive behavioral therapies for insomnia: sleep restriction (SR) and cognitive therapy (CT) in comparison to combined SR and CT (SR+CT).
Stanford is currently not accepting patients for this trial. For more information, please contact Alison Buchanan, 650-849-0584.
Alzheimer's Disease Neuroimaging Initiative 2 Not Recruiting
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.
Stanford is currently not accepting patients for this trial. For more information, please contact Michael Nolasco, 650-849-0491.
The Effectiveness of rTMS in Depressed VA Patients Recruiting
The purpose of this multi-site trial is to determine if repetitive Transcranial Magnetic Stimulation (rTMS) helps people with depression who have not been helped by medications or who have not been helped enough by medications.
Post Traumatic Stress Disorder (PTSD), Sleep Disordered Breathing And Genetics: Effects On Cognition Not Recruiting
The current research program aims to study how sleep disordered breathing, age and genetics affect memory in older adult veterans with Posttraumatic Stress Disorder (PTSD). The study will help researchers and clinicians better understand the relationship among PTSD, sleep disordered breathing, genetics and memory function.
Stanford is currently not accepting patients for this trial. For more information, please contact Timothy Kimball, PhD, 650-493-5000 Ext. 60482.
A Study of Brain Aging in Vietnam War Veterans Recruiting
Traumatic brain injury (TBI) and post traumatic stress disorder (PTSD) are common combat related problems and may be associated with a greater risk of Alzheimer's disease (AD). The purpose of this study is to examine the possible connections between TBI and PTSD, and the signs and symptoms of AD on Veterans as they age. The information collected will help to learn more about how these injuries may affect Veterans of the Vietnam War as they grow older, as well as Veterans of the current wars in Iraq and Afghanistan, who also have these types of combat related injuries.
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Not Recruiting
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
Stanford is currently not accepting patients for this trial. For more information, please contact Tamara Beale, 650-852-3234.
Age-related Longitudinal Changes in Aviator Performance Not Recruiting
Our overall goal has been twofold: 1) to evaluate whether there are significant age-related changes in flight simulator performance near age 60, and 2) to assess whether there is an alternative model that can explain longitudinal flight simulator performance on the basis of measures of cognitive function and expertise.
Stanford is currently not accepting patients for this trial. For more information, please contact Daniel Heraldez, 650-852-3457.
